ARID1A and neoplasm: We confirmed that ARID1A mutations are associated with elevated immune activity in GI cancers and demonstrated that the increased tumor mutation load and reduced tumor aneuploidy in ARID1A-mutated GI cancers may explain the more active immune signatures in ARID1A-mutated GI cancers versus ARID1A-wildtype GI cancers.